SCHEMBL14964102

SCHEMBL14964102

N#CCc1c[nH]c2cc(CO)ccc12

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 3/20 0.54
GPR84 Q9NQS5 2/20 0.39
HTR2C P28335 2/20 0.39
HTR2A P28223 3/20 0.36
HTR2B P41595 1/20 0.36
NPC1 O15118 1/20 0.36
HASPIN Q8TF76 1/20 0.35
PRKAB2 O43741 2/20 0.35
PRKAG1 P54619 2/20 0.35
PRKAA2 P54646 2/20 0.35
PRKAA1 Q13131 2/20 0.35
PRKAG3 Q9UGI9 2/20 0.35
PRKAG2 Q9UGJ0 2/20 0.35
PRKAB1 Q9Y478 2/20 0.35
MAOA P21397 1/20 0.35
DYRK1A Q13627 1/20 0.35
MPO P05164 1/20 0.35
SLC6A4 P31645 1/20 0.35
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14964100 0.88 CSNK2A1 (0.63) CSNK2A1GPR84HTR2CHTR2AHTR2B
SCHEMBL11924849 0.84 CSNK2A1 (0.54) CSNK2A1GPR84HTR2CHTR2AHTR2B
SCHEMBL1242939 0.78 GPR84 (0.67) CSNK2A1GPR84HTR2CHTR2AMPO
SCHEMBL29352833 0.78 GPR84 (0.67) CSNK2A1GPR84HTR2CHTR2AMPO
SCHEMBL6198753 0.78 GPR84 (0.67) CSNK2A1GPR84HTR2ADYRK1ASLC6A4
SCHEMBL273402 0.78 CSNK2A1 (0.57) CSNK2A1GPR84HTR2CHTR2AMPO
SCHEMBL15074715 0.78 HTR2A (0.59) CSNK2A1GPR84HTR2CHTR2AHTR2B
SCHEMBL29354243 0.78 CSNK2A1 (0.77) CSNK2A1GPR84HTR2CHTR2ASLC6A4
SCHEMBL18708142 0.78 CSNK2A1 (0.57) CSNK2A1GPR84HTR2CHTR2AHTR2B
SCHEMBL6029334 0.78 CSNK2A1 (0.77) CSNK2A1GPR84HTR2CHTR2ASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212138-B2 Use of derivatives of indoles for the treatment of cancer COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-12-15 US disclosed
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-08-21 US disclosed
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT CSNK2A1 455/4885GPR84 2037/4885HTR2C 28/4885
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT CSNK2A1 455/4885GPR84 2037/4885HTR2C 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.